Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology
- PMID: 26149884
- DOI: 10.1016/S1470-2045(15)00076-5
Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology
Abstract
The management of primary CNS lymphoma is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the very few controlled studies available. In 2013, the European Association of Neuro-Oncology created a multidisciplinary task force to establish evidence-based guidelines for immunocompetent adults with primary CNS lymphoma. In this Review, we present these guidelines, which provide consensus considerations and recommendations for diagnosis, assessment, staging, and treatment of primary CNS lymphoma. Specifically, we address aspects of care related to surgery, systemic and intrathecal chemotherapy, intensive chemotherapy with autologous stem-cell transplantation, radiotherapy, intraocular manifestations, and management of elderly patients. The guidelines should aid clinicians in their daily practice and decision making, and serve as a basis for future investigations in neuro-oncology.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Similar articles
-
Treatment options for central nervous system lymphomas in immunocompetent patients.Expert Rev Neurother. 2009 Oct;9(10):1497-509. doi: 10.1586/ern.09.100. Expert Rev Neurother. 2009. PMID: 19831839
-
Therapeutic management of primary CNS lymphoma in immunocompetent patients.Expert Rev Anticancer Ther. 2001 Oct;1(3):382-94. doi: 10.1586/14737140.1.3.382. Expert Rev Anticancer Ther. 2001. PMID: 12113105 Review.
-
[Primary CNS lymphoma--an update].Bull Cancer. 2014 Mar;101(3):314-24. doi: 10.1684/bdc.2014.1909. Bull Cancer. 2014. PMID: 24691194 Review. French.
-
First-line autologous stem cell transplantation in primary CNS lymphoma.Eur J Haematol. 2005 Oct;75(4):288-92. doi: 10.1111/j.1600-0609.2005.00508.x. Eur J Haematol. 2005. PMID: 16146534 Clinical Trial.
-
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL).Neuro Oncol. 2023 Jan 5;25(1):37-53. doi: 10.1093/neuonc/noac196. Neuro Oncol. 2023. PMID: 35953526 Free PMC article.
Cited by
-
Flow cytometry identifies changes in peripheral and intrathecal lymphocyte patterns in CNS autoimmune disorders and primary CNS malignancies.J Neuroinflammation. 2024 Nov 4;21(1):286. doi: 10.1186/s12974-024-03269-3. J Neuroinflammation. 2024. PMID: 39497174 Free PMC article.
-
Differentiating between Lymphoma and Metastasis Presenting as Solid Cerebellar Mass Lacking Necrosis.Diagnostics (Basel). 2024 Oct 6;14(19):2228. doi: 10.3390/diagnostics14192228. Diagnostics (Basel). 2024. PMID: 39410632 Free PMC article.
-
Prognostic Impacts of Age, Diagnosis Time, and Relapses in Primary CNS Lymphoma.J Clin Med. 2024 Aug 13;13(16):4745. doi: 10.3390/jcm13164745. J Clin Med. 2024. PMID: 39200887 Free PMC article.
-
The Prognostic Significance of Pontine-White Matter Score in Primary Central Nervous System Lymphoma Patients.Cancers (Basel). 2024 Jul 30;16(15):2708. doi: 10.3390/cancers16152708. Cancers (Basel). 2024. PMID: 39123436 Free PMC article.
-
Autoimmune encephalitis followed by hemophagocytic lymph histiocytosis: a case report.Front Immunol. 2024 Jul 22;15:1383255. doi: 10.3389/fimmu.2024.1383255. eCollection 2024. Front Immunol. 2024. PMID: 39104535 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical

